ESC Premium Access

Q&A - Clinical considerations for cardiologists: exploring the evidence for primary and secondary prevention in type 2 diabetes.

Presentation

About the speakers

Professor Nikolaus Marx

RWTH University Hospital Aachen, Aachen (Germany)
26 presentations
0 follower

Doctor Paul Wayne Armstrong

University of Alberta, Edmonton (Canada)
9 presentations
0 follower

Professor Lars Ryden

Department of medicine, Karolinska Institutet, Stockholm, Stockholm (Sweden)
31 presentations
0 follower

Professor Lawrence Leiter

University of Toronto, Toronto (Canada)
18 presentations
0 follower

6 more presentations in this session

Welcome and introduction - Clinical considerations for cardiologists: exploring the evidence for primary and secondary prevention in type 2 diabetes.

Speaker: Associate Professor G. De Ferrari (Pavia, IT) Professor L. Leiter (Toronto, CA)

Thumbnail

Coprevalence of comorbidities and their role in the choices of treatment for the diabetic patient with cardiovascular disease.

Speaker: Professor N. Marx (Aachen, DE)

Thumbnail

Newly emerging data from the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial: an investigator’s perspective.

Speaker: Doctor P. Armstrong (Edmonton, CA)

Thumbnail

Diabetes cardiovascular safety trials: an endocrinologist’s interpretation of emergent data.

Speaker: Professor L. Leiter (Toronto, CA)

Thumbnail

Closing the gap: the EUROASPIRE study (European Action on Secondary Prevention by Intervention to Reduce Events) and what it can tell us for the treatment of diabetes patients.

Speaker: Professor L. Ryden (Stockholm, SE)

Thumbnail

Access the full session

Clinical considerations for cardiologists: exploring the evidence for primary and secondary prevention in type 2 diabetes

Speakers: Professor N. Marx, Doctor P. Armstrong, Professor L. Ryden, Professor L. Leiter, Associate Professor G. De Ferrari...
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

This platform is supported by

logo Novo Nordisk